Application of chemoproteomics to drug discovery: Identification of a clinical candidate targeting Hsp90

Chemistry and Biology

Volumn 17, Issue 7, 2010, Pages 686-694

  Fadden, Patrick ^a   Huang, Kenneth H ^a   Veal, James M ^a   Steed, Paul M ^a   Barabasz, Amy F ^a   Foley, Briana ^a   Hu, Mei ^a   Partridge, Jeffrey M ^a   Rice, John ^a   Scott, Anisa ^a   Dubois, Laura G ^a   Freed, Tiffany A ^a   Silinski, Melanie A Rehder ^a   Barta, Thomas E ^a   Hughes, Philip F ^a   Ommen, Andy ^a   Ma, Wei ^a   Smith, Emilie D ^a   Spangenberg, Angela Woodward ^a   Eaves, Jeron ^a   Hanson, Gunnar J ^a   Hinkley, Lindsay ^a   Jenks, Matthew ^a   Lewis, Meredith ^a   Otto, James ^a   Pronk, Gijsbertus J ^a   Verleysen, Katleen ^a   Haystead, Timothy A ^b   Hall, Steven E ^a   more..

^a Serenex Inc   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CHEMBIO; PROTEINS

Indexed keywords

ADENOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN 90; MOLECULAR LIBRARY;

ANIMAL; ARTICLE; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG SCREENING; ENZYME SPECIFICITY; FEMALE; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; MOUSE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PROTEOMICS; ADMINISTRATION AND DOSAGE; ANTAGONISTS AND INHIBITORS; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEOMICS; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EID: 77955444211     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.04.015     Document Type: Article

References (50)

1. U. Banerji Heat shock protein 90 as a drug target: some like it hot Clin. Cancer Res. 15 2009 9 14
2. M. Bantscheff , D. Eberhard , Y. Abraham , S. Bastuck , M. Boesche , S. Hobson , T. Mathieson , J. Perrin , M. Raida , and C. Rau Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 2007 1035 1044
3. T.E. Barta , J.M. Veal , J.W. Rice , J.M. Partridge , R.P. Fadden , W. Ma , M. Jenks , L. Geng , G.J. Hanson , and K.H. Huang Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90 Bioorg. Med. Chem. Lett. 18 2008 3517 3521
4. P.A. Brough , W. Aherne , X. Barril , J. Borgognoni , K. Boxall , J.E. Cansfield , K.M. Cheung , I. Collins , N.G. Davies , and M.J. Drysdale 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 51 2008 196 218
5. S.K. Calderwood , M.A. Khaleque , D.B. Sawyer , and D.R. Ciocca Heat shock proteins in cancer: chaperones of tumorigenesis Trends Biochem. Sci. 31 2006 164 172
6. Carrez, C., Fassy, F., Mailliet, P. (2006). PCT Int. Appl. WO2006075095.
7. S. Chandarlapaty , A. Sawai , Q. Ye , A. Scott , M. Silinski , K. Huang , P. Fadden , J. Partdrige , S. Hall , and P. Steed SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers Clin. Cancer Res. 14 2008 240 248
8. G. Chiosis , and H. Tao Purine-scaffold Hsp90 inhibitors IDrugs 9 2006 778 782
9. G. Chiosis , M. Vilenchik , J. Kim , and D. Solit Hsp90: the vulnerable chaperone Drug Discov. Today 9 2004 881 888
10. J.S. Duncan , L. Gyenis , J. Lenehan , M. Bretner , L.M. Graves , T.A. Haystead , and D.W. Litchfield An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets Mol. Cell. Proteomics 7 2008 1077 1088
11. B.W. Dymock , X. Barril , P.A. Brough , J.E. Cansfield , A. Massey , E. McDonald , R.E. Hubbard , A. Surgenor , S.D. Roughley , and P. Webb Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design J. Med. Chem. 48 2005 4212 4215
12. Eggenweiler, H., Wolf, M. November 2006. PCT Int. Appl. WO2006125531.
13. Eggenweiler, H., Wolf, M., Buchstaller, H. November 2006. PCT Int. Appl. WO2006122631.
14. L. Esser , C.R. Wang , M. Hosaka , C.S. Smagula , T.C. Südhof , and J. Deisenhofer Synapsin I is structurally similar to ATP-utilizing enzymes EMBO J. 17 1998 977 984
15. R.D. Finn , J. Tate , J. Mistry , P.C. Coggill , S.J. Sammut , H.R. Hotz , G. Ceric , K. Forslund , S.R. Eddy , E.L. Sonnhammer , and A. Bateman The Pfam protein families database Nucleic Acids Res. 36 2008 D281 D288
16. GAO-07-49. (2006). New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts, United States Government Accountability Office Report to Congressional Requesters.
17. F. Gharahdaghi , C.R. Weinberg , D.A. Meagher , B.S. Imai , and S.M. Mische Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity Electrophoresis 20 1999 601 605
18. L.T. Gooljarsingh , C. Fernandes , K. Yan , H. Zhang , M. Grooms , K. Johanson , R.H. Sinnamon , R.B. Kirkpatrick , J. Kerrigan , and T. Lewis A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues Proc. Natl. Acad. Sci. USA 103 2006 7625 7630
19. P.R. Graves , J.J. Kwiek , P. Fadden , R. Ray , K. Hardeman , A.M. Coley , M. Foley , and T.A. Haystead Discovery of novel targets of quinoline drugs in the human purine binding proteome Mol. Pharmacol. 62 2002 1364 1372
20. G. Guillerm , M. Muzard , C. Glapski , S. Pilard , and E. De Clercq Inactivation of S-adenosyl-L-homocysteine hydrolase by 6′-cyano-5′, 6′-didehydro-6′-deoxyhomoadenosine and 6′-chloro-6′- cyano-5′,6′-didehydro-6′-deoxyhomoadenosine. Antiviral and cytotoxic effects J. Med. Chem. 49 2006 1223 1226
21. Hanson, G.J., Barta, T.E., Veal, J.M., Ware, R.W. February 2006. PCT Int. Appl. WO2006014706.
22. Hardeman, K., Hall, S.E., Ware, R.W., Hinckley, L.A., Jenks, M.G. August 2004. PCT Int. Appl. WO2004065566.
23. H.J. Harwood Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome Curr. Opin. Investig. Drugs 5 2004 283 289
24. T.A. Haystead The purinome, a complex mix of drug and toxicity targets Curr. Top. Med. Chem. 6 2006 1117 1127
25. K.H. Huang , J.M. Veal , R.P. Fadden , J.W. Rice , J. Eaves , J.P. Strachan , A.F. Barabasz , B.E. Foley , T.E. Barta , and W. Ma Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents J. Med. Chem. 52 2009 4288 4305
26. R.M. Immormino , Y. Kang , G. Chiosis , and D.T. Gewirth Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors J. Med. Chem. 49 2006 4953 4960
27. Y.L. Janin Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 48 2005 7503 7512
28. S.R. Kasibhatla , K. Hong , M.A. Biamonte , D.J. Busch , P.L. Karjian , J.L. Sensintaffar , A. Kamal , R.E. Lough , J. Brekken , and K. Lundgren Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity J. Med. Chem. 50 2007 2767 2778
29. Machajewski, T.D., Zhenhai, G., Levine, B.H., William, A., Bellamacina, C., Costales, A., Doughan, B.M., Fong, S., Hendrickson, T., Lin, X., et al. October 2006). PCT Int. Appl. WO2006113498.
30. L. Neckers Heat shock protein 90: the cancer chaperone J. Biosci. 32 2007 517 530
31. W.M. Obermann , H. Sondermann , A.A. Russo , N.P. Pavletich , and F.U. Hartl In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis J. Cell Biol. 143 1998 901 910
32. B. Panaretou , C. Prodromou , S.M. Roe , R. O'Brien , J.E. Ladbury , P.W. Piper , and L.H. Pearl ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo EMBO J. 17 1998 4829 4836
33. M.P. Patricelli , A.K. Szardenings , M. Liyanage , T.K. Nomanbhoy , M. Wu , H. Weissig , A. Aban , D. Chun , S. Tanner , and J.W. Kozarich Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 46 2007 350 358
34. L.H. Pearl , and C. Prodromou Structure and mechanism of the Hsp90 molecular chaperone machinery Annu. Rev. Biochem. 75 2006 271 294
35. M.V. Powers , and P. Workman Inhibitors of the heat shock response: biology and pharmacology FEBS Lett. 581 2007 3758 3769
36. W.B. Pratt , and D.O. Toft Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery Exp. Biol. Med. (Maywood) 228 2003 111 133
37. C. Prodromou , S.M. Roe , R. O'Brien , J.E. Ladbury , P.W. Piper , and L.H. Pearl Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 90 1997 65 75
38. S.M. Roe , C. Prodromou , R. O'Brien , J.E. Ladbury , P.W. Piper , and L.H. Pearl Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J. Med. Chem. 42 1999 260 266
39. J. Rosenfeld , J. Capdevielle , J.C. Guillemot , and P. Ferrara In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis Anal. Biochem. 203 1992 173 179
40. T.W. Schulte , S. Akinaga , S. Soga , W. Sullivan , B. Stensgard , D. Toft , and L.M. Neckers Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin Cell Stress Chaperones 3 1998 100 108
41. S.V. Sharma , T. Agatsuma , and H. Nakano Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol Oncogene 16 1998 2639 2645
42. D.B. Solit , and G. Chiosis Development and application of Hsp90 inhibitors Drug Discov. Today 13 2008 38 43
43. C.E. Stebbins , A.A. Russo , C. Schneider , N. Rosen , F.U. Hartl , and N.P. Pavletich Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 89 1997 239 250
44. UniProt Consortium The universal protein resource (UniProt) Nucleic Acids Res. 36 2008 D190 D195
45. M. Vilenchik , D. Solit , A. Basso , H. Huezo , B. Lucas , H. He , N. Rosen , C. Spampinato , P. Modrich , and G. Chiosis Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90 Chem. Biol. 11 2004 787 797
46. C.L. Vogel , M.A. Cobleigh , D. Tripathy , J.C. Gutheil , L.N. Harris , L. Fehrenbacher , D.J. Slamon , M. Murphy , W.F. Novotny , and M. Burchmore Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 20 2002 719 726
47. T. Sørensen A method of establishing groups of equal amplitude in plant sociology based on similarity of species and its application to analyses of the vegetation on Danish commons Biologiske Skrifter / Kongelige Danske Videnskabernes Selskab 5 1948 1 34
48. L. Whitesell , and S.L. Lindquist HSP90 and the chaperoning of cancer Nat. Rev. Cancer 5 2005 761 772
49. L. Whitesell , E.G. Mimnaugh , B. De Costa , C.E. Myers , and L.M. Neckers Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. USA 91 1994 8324 8328
50. L. Wright , X. Barril , B. Dymock , L. Sheridan , A. Surgenor , M. Beswick , M. Drysdale , A. Collier , A. Massey , and N. Davies Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms Chem. Biol. 11 2004 775 785